Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)

Research

BMJ 2015; 351 doi: https://doi.org/10.1136/bmj.h5364 (Published 28 October 2015) Cite this as: BMJ 2015;351:h5364

Data supplement

Web Extra

Extra material supplied by the author

Data Supplement - Web material: supplementary appendix

Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression
- Abstract
- Fulltext
- PDF
Switching From Insulin Bolus Treatment to GLP-1 RAs Added to Continued Basal Insulin in People With Type 2 Diabetes on Basal-Bolus Insulin
- Abstract
- Fulltext
- PDF
Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial
- Abstract
- Fulltext
- PDF
Analysis and reporting of adverse events in randomised controlled trials: a review
- Abstract
- Fulltext
- PDF
Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3)
- Abstract
- Fulltext
- PDF
Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials
- Abstract
- Fulltext
- PDF
When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump
- Abstract
- Fulltext
- PDF